Evaluation of the EndoPAT as a Tool to Assess Endothelial Function

Table 4

Augmentation index.

Population	𝑁	Therapy	Study period	mean ± SD	min–max
Renal patients	6	N/A	N/A^#	26.1±13.9 *	13.3–52.0
Diabetic patients	8	Metformin	cont	5.9±9.4 **	−8.0–22.0
Diabetic patients	8	Metformin	discont	14.3±18.9 **	1.0–55.0
Diabetic patients	8	Metformin + SA	cont	9.0±13.0^**, ***	−15.0–24.0
Diabetic patients	8	Metformin + SA	discont	16.3±16.0^**, ***	−6.0–32.0
Healthy volunteers	12	N/A	N/A	−6.0±14.2	−25.7–31.7

SA: sulfonylurea; SD: standard deviation.
Cont: continuation of therapy; discount: 2 weeks of therapy discontinuation.
^#visit 1, 2, and 3 and averaged (see materials and methods).
* 𝑃=0.001 versus healthy volunteers.
** 𝑃<0.05 versus healthy volunteers.
*** 𝑃<0.05 versus diabetic patients on metformin only.